MDV#

Related by string. * * commercialize MDV# *

Related by context. All words. (Click for frequent words.) 71 alvespimycin 70 HGS ETR1 70 Tyrima 69 ganetespib 68 OXi# 68 phase IIa clinical 68 ELACYT 68 R#/MEM # 68 AEG# 68 PXD# 68 phase IIb clinical 68 CR# vcMMAE 67 IMC A# 67 INCB# [001] 67 tesetaxel 67 XmAb# 67 Zolinza 67 pertuzumab 67 Azedra 67 enzastaurin 67 MGCD# [001] 66 seliciclib 66 ISIS # 66 HuMax CD# 66 metastatic hormone refractory 66 LY# [003] 66 Panzem R NCD 66 Symadex 66 delafloxacin 66 TACI Ig 66 CBLC# 66 PSMA ADC 66 tanespimycin 66 Asentar 66 Serdaxin 66 elotuzumab 66 JAK1 66 evaluating tivozanib 66 BAY #-# 66 GRN#L 65 CCX# 65 JAK inhibitor 65 AP# [003] 65 INCB# [003] 65 Targretin 65 Carfilzomib 65 axitinib 65 YONDELIS 65 rNAPc2 65 Aplidin 65 Sym# 65 eniluracil 65 PEG SN# 65 BZL# 65 Xanafide 65 Bicifadine 65 orally administered inhibitor 65 PSN# [002] 65 belinostat 65 registrational trial 65 metaglidasen 65 abiraterone 65 Bortezomib 65 huC# DM4 65 Tarvacin 65 HER2 positive metastatic breast 65 Phase Ib clinical 65 Ophena TM 65 ASA# 65 AZD# 65 MEK inhibitors 65 HGS ETR2 64 RG# [001] 64 Phase Ib 64 HuMax EGFr 64 deforolimus 64 Phase Ib study 64 ocrelizumab 64 Traficet EN 64 entinostat 64 PDE4 inhibitor 64 MAGE A3 ASCI 64 Atiprimod 64 oral prodrug 64 vemurafenib 64 Bezielle 64 ELND# 64 selective androgen receptor modulator 64 Tesetaxel 64 mapatumumab 64 Cethromycin 64 Archexin 64 PRX # 64 PRTX 64 atrasentan 64 HQK 64 TRIOLEX 64 HuLuc# 64 CA4P 64 epigenetic therapies 64 obatoclax 64 dacetuzumab 64 PRT# 64 decitabine 64 sunitinib malate 64 atacicept 64 DXL# 64 dimebon 64 custirsen 64 SERMs 64 EOquin TM 64 AVE# 64 darapladib 64 HCD# [002] 64 MEK inhibitor 64 Cloretazine ® 64 SAR# [004] 64 sorafenib Nexavar 64 TRO# 64 XL# [003] 64 trastuzumab DM1 64 CoFactor 64 EndoTAG TM -1 64 IMA# 64 OHR/AVR# 64 Mipomersen 63 tesmilifene 63 BRIM3 63 sodium glucose cotransporter 63 cediranib 63 Talabostat 63 Tarvacin TM 63 PS# [001] 63 forodesine 63 Amrubicin 63 HGS# 63 vidofludimus 63 diabetic neuropathic pain 63 olaparib 63 orally bioavailable 63 OncoVEX GM CSF 63 Aflibercept 63 talabostat 63 PF # [001] 63 DCCR 63 adecatumumab 63 Pimavanserin 63 GFT# 63 vorinostat 63 Glufosfamide 63 BRAF inhibitor 63 MGd 63 epothilone 63 ENMD # 63 pralatrexate 63 ixabepilone 63 Rebif ® 63 BRIM2 63 pan HDAC inhibitor 63 Imprime PGG 63 muraglitazar 63 PCK# 63 Onconase 63 Dasatinib 63 mipomersen 63 Dapagliflozin 63 Androxal TM 63 Randomized Phase 63 vascular disrupting agent 63 GVAX 63 PLK1 SNALP 63 PD LID 63 Ceflatonin 63 Angiolix 63 Aurexis 63 GV# [001] 63 metastatic castration resistant 63 glufosfamide 63 ALN TTR 63 PEG PAL 63 castrate resistant prostate cancer 63 CCR9 antagonist 63 sapacitabine 63 panitumumab 63 Abiraterone acetate 63 elesclomol 63 RDEA# 63 Perifosine 63 AEGR 63 talactoferrin 63 HuMax CD4 63 NGX# 63 tezampanel 63 Allovectin 7 R 63 zanolimumab 63 docetaxel Taxotere R 63 Triolex 62 RGB # 62 LymphoStat B 62 Zerenex 62 HspE7 62 ongoing Phase 1b 62 Annamycin 62 PEG Interferon lambda 62 INCB# [002] 62 bardoxolone 62 IMC #B 62 radiation sensitizer 62 Phase 2a trial 62 L BLP# 62 pomalidomide 62 lomitapide 62 tocilizumab 62 Alocrest 62 multi kinase inhibitor 62 nicotinic alpha 7 62 Panzem R 62 TKM ApoB 62 daclizumab 62 OMP #M# 62 Troxatyl 62 Cetrorelix 62 MYDICAR ® 62 receptor tyrosine kinase inhibitor 62 bicalutamide 62 Daclizumab 62 relapsed multiple myeloma 62 Rasagiline 62 vosaroxin 62 Elotuzumab 62 cilengitide 62 Guanilib 62 Thiovir 62 otelixizumab 62 Sapacitabine 62 Tamibarotene 62 IRX 2 62 T DM1 62 CD# antibody [001] 62 telomerase therapeutic 62 Chemophase 62 investigational humanized monoclonal antibody 62 OvaRex R 62 CYC# 62 Phase #/#a 62 Elvitegravir 62 Thiarabine 62 lintuzumab 62 RhuDex ® 62 Laquinimod 62 dose escalation Phase 62 CYT# potent vascular disrupting 62 phase Ib 62 fosbretabulin 62 Corlux 62 IAP inhibitors 62 castration resistant prostate cancer 62 selective modulator 62 torezolid phosphate 62 angiogenesis inhibitor 62 KRN# 62 hematological cancers 62 CEQ# 62 Clolar ® 62 selective kinase inhibitor 62 erlotinib Tarceva ® 62 Phase 2a 62 neratinib 62 tolvaptan 62 TOCOSOL Paclitaxel 62 androgen independent 62 IMGN# 62 eprotirome 62 Omacetaxine 62 Phase 1b 62 ToGA 62 proteasome inhibitor 62 Proxinium TM 62 Capesaris 62 ospemifene 62 Virulizin ® 62 Squalamine 62 Fulvestrant 62 eltrombopag 62 Telbivudine 62 OMP #R# 62 Posiphen 61 Lenocta 61 Exelixis XL# 61 sorafenib Nexavar ® 61 refractory gout 61 Panzem 61 EndoTAGTM 1 61 iniparib 61 Tezampanel 61 betrixaban 61 Tanespimycin 61 Ridaforolimus 61 CD3 monoclonal antibody 61 KNS # 61 liposomal formulation 61 CYT# 61 Nexavar ® 61 imetelstat 61 ZOLINZA 61 DAVANAT 61 relapsed MM 61 Neuradiab 61 Reverset 61 ALN PCS 61 Lu AA# 61 aleglitazar 61 docetaxel chemotherapy 61 virus HCV protease inhibitor 61 Synavive 61 Cloretazine VNP#M 61 metastatic castrate resistant 61 BioNumerik 61 abiraterone acetate 61 Phenoptin 61 preclinically 61 Oral NKTR 61 ocular formulation 61 Elesclomol 61 trastuzumab DM1 T DM1 61 Romidepsin 61 ON #.Na 61 JAK inhibitors 61 T#I [002] 61 hematological malignancies 61 EOquin 61 myeloproliferative disorders 61 Phase IIb clinical trials 61 FOLOTYN ® 61 vandetanib 61 NXL# 61 reslizumab 61 severe hypercholesterolemia 61 elacytarabine 61 GAP #B# 61 Xinlay 61 RAV# 61 radezolid 61 DOS# 61 phase IIb 61 teplizumab 61 afatinib 61 celgosivir 61 Ophena 61 Viprinex 61 CD# monoclonal antibody 61 Ceflatonin R 61 Zalbin 61 lorvotuzumab mertansine 61 Insegia 61 aflibercept 61 Amigal 61 MEK inhibitor RDEA# 61 Azedra TM 61 pradefovir 61 investigational monoclonal antibody 61 figitumumab 61 TASQ 61 Phase 1b trial 61 Telaprevir 61 PDX pralatrexate 61 methylnaltrexone 61 thymalfasin 61 oral ridaforolimus 61 Voreloxin 61 Kahalalide F 61 HCV protease inhibitor 61 Stedivaze 61 anidulafungin 61 goserelin 61 XYOTAX TM 61 Quinamed 61 PrevOnco 61 assessing T DM1 61 velafermin 61 placebo controlled Phase 61 cangrelor 61 nucleoside 61 Personalized Immunotherapy 61 HCV protease 61 ALN TTR# 61 pegylated interferons 61 depsipeptide 61 Azixa 61 ambrisentan 61 GW# [003] 61 TREANDA 61 Naproxcinod 61 Ramoplanin 61 nucleoside analogue 61 Belinostat 61 Phase Ib II 61 Plicera 61 chemopreventive agent 61 HGS ETR1 mapatumumab 61 Phase #b/#a clinical 61 #ME# 61 hormone refractory prostate cancer 61 huN# DM1 61 BCX# 61 Cloretazine R VNP#M 61 Hsp# inhibitors 61 veltuzumab 61 JAK2 inhibitor 60 dose cohorts 60 ataluren 60 CRLX# 60 uric acid lowering 60 azacitidine 60 AQ4N 60 galiximab 60 Iloperidone 60 Amplimexon 60 SCH # 60 GSK# [002] 60 Debio 60 regorafenib 60 Curaxin 60 tiapamil 60 Cloretazine 60 cannabinor 60 mTOR inhibitor 60 Phase #b/#a trial 60 SPC# [001] 60 Pralatrexate 60 integrase inhibitor 60 NU# [001] 60 Phase IIb trials 60 NVA# 60 CDK inhibitor 60 Acapodene 60 PROSTVAC TM 60 preclinical 60 TLK# 60 Jevtana 60 proteasome inhibitors 60 GRN# 60 ozarelix 60 Genz # 60 vascular disrupting agents 60 Nanobody 60 bevacizumab Avastin ® 60 XL# XL# XL# 60 Vilazodone 60 Zoraxel 60 Hsp# inhibition 60 ALN VSP 60 Nuvion 60 cMET 60 bortezomib 60 Ocrelizumab 60 antithrombotic 60 Gleevec resistant 60 phase 2a 60 antibody MAb 60 Allovectin 7 60 ILLUMINATE 60 CLORETAZINE TM VNP#M 60 Phase #b/#a 60 registrational 60 BiTE antibody 60 APOPTONE 60 TAFA# 60 Genasense ® 60 targeting CD# 60 BMS # 60 voreloxin 60 anti amnesic 60 heavily pretreated 60 cabozantinib 60 Celgene Revlimid 60 Exemestane 60 pharmacokinetic PK study 60 IIa trial 60 interferon gamma 1b 60 CIMZIA TM 60 teriflunomide 60 dexpramipexole 60 GSK # 60 anti leukemic 60 iSONEP 60 danoprevir 60 REOLYSIN ® 60 APEX PD 60 Pazopanib 60 Degarelix 60 lapatinib Tykerb 60 urocortin 2 60 Elocalcitol 60 Phase IIIb clinical 60 epothilones 60 humanized anti 60 CTAP# Capsules 60 GAMMAGARD 60 ONCONASE R 60 GSK '# 60 IL# PE#QQR 60 ZYBRESTAT 60 imatinib Gleevec ® 60 GLP toxicology studies 60 oral Azacitidine 60 TG# [001] 60 Aplidin R 60 midstage clinical 60 mRCC 60 novel VDA molecule 60 TriRima 60 ACTIVE W 60 Linaclotide 60 phase IIb study 60 SinuNase 60 Tavocept 60 Avicena 60 ThermoDox R 60 MLN# 60 dirucotide 60 Teplizumab 60 S/GSK# 60 valopicitabine 60 Epanova 60 perifosine 60 relapsed refractory multiple myeloma 60 VIDAZA 60 TELCYTA 60 Safinamide 60 Sudhir Agrawal D.Phil 60 Phase 2b study 60 Azacitidine 60 Phase 2a clinical 60 bendamustine 60 viral kinetics 60 acyclovir Lauriad R 60 YONDELIS R 60 mertansine 60 Golimumab 60 Apoptone 60 erlotinib Tarceva 60 AZILECT R 60 prostate cancer AIPC 60 Trofex 60 anti CD# antibodies 60 cetuximab Erbitux 60 Vidofludimus 60 Factor VIIa 60 Hsp# inhibitor 60 Solazed TM 60 Dalbavancin 60 Trastuzumab 60 Epothilones 60 generation antisense 60 Menerba 60 MKC# MT 60 trabectedin 60 ATL# [001] 60 tyrosine kinase inhibitor 60 trodusquemine 60 Tocosol Paclitaxel 60 EFAPROXYN 60 SCCHN 60 ZK EPO 60 CORT # 60 palifosfamide Zymafos TM 60 Herceptin trastuzumab 60 cabazitaxel 60 Zybrestat 60 romidepsin 60 cancer immunotherapies 60 Vaprisol 60 MERLIN TIMI 60 PLX# 59 Copegus ribavirin 59 TMC# [002] 59 MYDICAR 59 Phase Ib clinical trials 59 tafamidis 59 bevacizumab Avastin 59 anti EGFR antibody 59 OncoVEX 59 Prostate AdenoCarcinoma Treatment 59 PNP inhibitor 59 leukemia AML 59 sorafenib tablets 59 PF # [002] 59 tarenflurbil 59 Vandetanib 59 metastatic renal cell 59 Phase 1a clinical 59 bexarotene 59 leading oral taxane 59 ANAVEX #-# [003] 59 Phase IIB 59 seliciclib CYC# 59 eculizumab 59 endothelin receptor antagonists 59 tasocitinib 59 oral JAK1 59 compound AEZS 59 forodesine hydrochloride 59 TG# [003] 59 ceftaroline 59 oral rivaroxaban 59 Triapine 59 motesanib 59 Pivotal Phase 59 phase IIa 59 sipuleucel T 59 ANG# 59 GLYX 59 VA# [002] 59 APD# 59 CINQUIL 59 cariprazine 59 multicenter Phase II 59 EP #R 59 chemotherapeutic drug 59 GRNVAC1 59 farletuzumab 59 GSK# [001] 59 riociguat 59 PEGylated 59 AzaSite Plus 59 glucokinase activator 59 Aurora kinase 59 Exherin TM 59 HSP# inhibitor 59 Tarceva TM 59 TRAIL receptor antibodies 59 ASONEP 59 LT NS# 59 Temsirolimus 59 ICA # 59 EDEMA3 59 Phase Ia 59 Vidaza 59 VEGF Trap 59 NP2 Enkephalin 59 XL# SAR# 59 FTY# 59 Blinatumomab 59 rFIXFc 59 Phase 2b clinical 59 tezampanel NGX# 59 ApoB SNALP 59 bazedoxifene 59 Androxal ® 59 Æterna Zentaris 59 standard chemotherapy regimen 59 ZACTIMA 59 CCX# B 59 Actemra 59 metastatic HRPC 59 rHuPH# 59 lesinurad 59 Gemzar ® 59 Advexin 59 Clofarabine 59 Lubiprostone 59 volociximab 59 IFN α 59 NPC 1C 59 anticancer therapies 59 AeroLEF TM 59 dasatinib Sprycel ® 59 flavopiridol 59 tecarfarin 59 paclitaxel Taxol 59 DAVANAT R 59 Phase IIb clinical 59 MT#/MEDI-# 59 gefitinib Iressa 59 cutaneous T cell 59 Cloretazine R 59 protein tyrosine phosphatase 1B 59 tubulin inhibitor 59 Seliciclib 59 tamibarotene 59 randomized controlled Phase 59 Aclidinium 59 modulator SERM 59 LUX Lung 59 PI3K inhibitor 59 vicriviroc 59 polymerase inhibitors 59 elvitegravir 59 myelofibrosis MF 59 maraviroc 59 prostate cancer CRPC 59 MAb 59 samalizumab 59 immunotherapeutic agent 59 picoplatin 59 ProSavin 59 RhuDex 59 CUDC 59 Relivar 59 FOLFOX6 chemotherapy regimen 59 BNC# 59 mTOR inhibitors 59 GVAX ® 59 drug pipeline TAFA# 59 trastuzumab Herceptin R 59 bavituximab 59 recurrent glioblastoma multiforme 59 GALNS 59 cancer mCRC 59 alvimopan 59 Pivotal Phase III 59 Saxagliptin 59 EGFR inhibitors 59 Milnacipran 59 Pemetrexed 59 initiated Phase Ib 59 ThGRF 59 SARMs 59 Ceflatonin ® 59 novel histone deacetylase 59 MAP# 59 vilazodone 59 Rigel R# 59 class mGluR5 inhibitor 59 Angiocept 59 viral kinetic 59 preclinical studies 59 Vitaxin 59 IDX# 59 Phase III Pivotal 59 posaconazole 59 generation nucleoside analog 59 NEUMUNE 59 Revlimid lenalidomide 59 brostallicin 59 bafetinib 59 Epratuzumab 59 favorable pharmacokinetic profile 59 Pirfenidone 59 oral deforolimus 59 protein kinase inhibitor 59 FLT3 59 Phase IIa trials 59 Pertuzumab 59 ZADAXIN 59 Gabapentin GR 59 temsirolimus 59 Neurodex 59 phase IIb trial 59 Elagolix 59 CXB# 59 apremilast 59 Cerimon 59 Chemokine 59 BLP# Liposome Vaccine 59 Fx #A 59 Albuferon 59 Fidaxomicin 59 hematologic malignancies 59 vascular disrupting 59 LHRH antagonist 59 Restanza 59 anticancer agent 59 Maraviroc 59 PRX# 59 luteinizing hormone releasing 59 Urocidin 59 Xelox 59 sitaxsentan 59 epratuzumab 59 adecatumumab MT# 59 UVIDEM 59 abatacept Orencia 59 p# biomarker 59 Valsartan 59 placebo controlled clinical 59 therapeutic monoclonal antibody 59 TRISENOX 59 Azedra ™ 59 blinded randomized placebo controlled 59 Onalta 59 PKC# 59 LEP ETU 59 RAPAFLO 59 Ozarelix 59 antitumor activity 59 pharmacokinetic PK 59 nilotinib 59 APTIVUS 59 antiangiogenic activity 59 ganaxolone 59 ACTEMRA TM 59 refractory chronic lymphocytic 58 ZD# [001] 58 oral Xeloda 58 mecamylamine 58 Boceprevir 58 ONCONASE 58 Desmoteplase 58 dasatinib 58 relapsed leukemia 58 Ambrisentan 58 XL# XL# 58 corticosteroid dexamethasone 58 gemcitabine Gemzar ® 58 BIBW 58 alkylating agent 58 antisense drug 58 dose cohort 58 SRT# [003] 58 XL# XL# XL# XL# 58 Eribulin 58 bortezomib Velcade 58 elagolix 58 docetaxel Taxotere ® 58 TKB# 58 mycophenolate mofetil 58 VAPRISOL 58 Folotyn 58 ANYARA 58 Clevudine 58 oral picoplatin 58 ularitide 58 carfilzomib 58 advanced metastatic prostate 58 ISTODAX 58 Ixempra 58 Enzastaurin 58 TBC# 58 Nexavar sorafenib 58 L Annamycin 58 BRAF V#E mutation 58 Talactoferrin 58 delta isoform 58 Vicriviroc 58 tremelimumab 58 drug conjugate 58 systemically administered 58 Silodosin 58 Actilon 58 JAK2 58 anticancer compound 58 IAP inhibitor 58 INT# [002] 58 Phase 2b Clinical Trial 58 UPLYSO 58 indibulin 58 laquinimod 58 ARIKACE ™ 58 LE DT 58 gefitinib 58 Sphingomab 58 Dacogen injection 58 prucalopride 58 superficial bladder cancer 58 Phase IIa trial 58 AKT inhibitor 58 TRV# [001] 58 lintuzumab SGN 58 EDEMA4 58 AMN# [001] 58 ENMD 58 Onco TCS 58 Phase 1b clinical trials 58 baminercept 58 sunitinib 58 Cleviprex TM clevidipine 58 Locteron 58 LymphoStat B TM 58 Tolerx 58 DU #b 58 myelofibrosis polycythemia vera 58 Ostarine 58 PDE# inhibitors 58 nitric oxide donating prostaglandin 58 ACZ# 58 Ziopharm 58 Solazed 58 Velcade bortezomib 58 nucleoside analog 58 Phase 2b trial 58 trastuzumab emtansine T DM1 58 Aliskiren 58 Phase #/#a trial 58 pediatric acute lymphoblastic 58 Darusentan 58 terlipressin 58 LCP AtorFen 58 CD# CEA 58 bicifadine 58 inhibitor RG# 58 CCR2 58 Clonicel 58 ruxolitinib 58 Panzem NCD 58 Abiraterone 58 pegylated liposomal doxorubicin 58 Valdoxan 58 fluvastatin 58 synthetic retinoid 58 Curaxin CBLC# 58 mitogen activated ERK kinase 58 Uricase PEG 58 Marqibo 58 lumiliximab 58 RE LY 58 ThermoDox ® 58 metastatic CRC 58 Erlotinib 58 Gefitinib 58 albinterferon alfa 2b 58 cetrorelix 58 Hedgehog pathway inhibitor 58 Preclinical studies suggest 58 Intravenous CP 58 refractory metastatic 58 Pegasys ® 58 nucleoside analogues 58 Epidermal Growth Factor Receptor 58 systemic RNAi therapeutic 58 insulin sensitizers 58 somatostatin analogue 58 Valortim ® 58 Ophthotech 58 Advaxis Phase 58 multicenter Phase 58 Multimeric 58 proteasome inhibitor bortezomib 58 solithromycin 58 immunomodulator 58 androgen receptor antagonist 58 eliglustat tartrate 58 ORENCIA R 58 Leukine ® 58 sulindac 58 HCV SPRINT 58 anti angiogenic 58 Tasimelteon 58 JAK2 inhibitors 58 relapsing remitting multiple sclerosis 58 Peregrine Pharmaceuticals 58 SNT MC# 58 aclidinium 58 cetuximab Erbitux ® 58 pramlintide 58 OMAPRO 58 TRC# 58 low dose cytarabine 58 Phase 2b clinical trials 58 compound INCB# 58 PROMACTA 58 BAL# [002] 58 PROVENGE 58 adipiplon 58 R#/MEM 58 CobaCyte 58 XmAb ® 58 ProMune 58 BCIRG 58 DPP4 inhibitor 58 ponatinib 58 EOquin TM phase 58 motesanib diphosphate 58 ZYBRESTAT fosbretabulin 58 Phase 1b clinical 58 glatiramer acetate 58 brivaracetam 58 ridaforolimus 58 subcutaneous formulation 58 Hepatocellular Carcinoma HCC 58 TNFerade 58 darinaparsin 58 MGCD# [002] 58 polymerase inhibitor 58 APPRAISE 58 SPIRIT IV 58 CIMZIA ™ 58 selective estrogen receptor 58 lasofoxifene 58 novel anticancer 58 recurrent ovarian cancer 58 Intarcia 58 multitargeted 58 Proellex TM 58 FOLOTYN 58 AVONEX ® 58 Hsp# Inhibitor 58 rFVIIIFc 58 eosinophilic asthma 58 apaziquone 58 dosing cohort 58 Catena ® 58 mGluR2 NAM 58 Bavituximab 58 oral antiviral 58 RSD# oral 58 CANCIDAS 58 rindopepimut

Back to home page